Accurate Education - Agmatine for Chronic Pain - A Screening Tool

Agmatine:

Agmatine Candidacy Screening Tool (ACST) for Chronic Pain Populations

The clinical indications for the use of agmatine in the management of chronic pain remain largely theoretical, based on pre-clinical and animal studies. However, the existing research is strongly, supportive of safety and potential benefits for the use of agmatine n chronic pain management, especially for patients on chronic opioid therapy.

The following section is based on AI (OpenEvidence) and is introduced here as a tool for determining potential benefit for supplementing with agmatine.

See:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Important Note

As with many OTC nutraceuticals, there is an evidence gap in which pre-clinical studies provide great support with evidence for Agmatine’s benefits in the management of chronic pain while there is very little evidence based on human studies. See below for more information.

Page Links:

CLINICIAN SUPPLEMENT

Agmatine Candidacy Screening Tool (ACST) for Chronic Pain Populations

Purpose: To identify pain patients most likely to benefit from agmatine supplementation based on targeting mechanisms associated with pain features and agmatine’s pharmacological profile. It is designed for integration into the 4-D Nutraceutical Protocol for chronic pain.

Instructions: Complete all 5 targets. Score each item as indicated. A higher total score suggests greater mechanistic alignment with agmatine’s analgesic targets.

This tool is intended to guide clinical reasoning, not to replace it.

—

TARGET 1: Central Sensitization Features (NMDA/Neuroplasticity Domain)

Score each item:

0 = Absent 1 = Mild/Occasional 2 = Moderate/Frequent 3 = Severe/Constant

_____ Pain that has spread beyond the original site of injury over time

_____ Pain from things that should not hurt (light touch, clothing, gentle pressure)

_____ Pain that seems too strong for what is physically wrong

_____ Being extra sensitive to light, sound, temperature, or odors

_____ Pain that builds up and gets worse with repeated touch or pressure in the same

spot

_____ Thinking problems that come with pain (brain fog, trouble focusing)

_____ Symptom flare-up after mild physical, mental, or emotional effort

Target 1 Subtotal: ___/21

—

TARGET 2: α₂-Adrenergic / Imidazoline Receptor Responsiveness

Rate your experiences:

1. Pain gets better during calming or relaxing states (e.g., pain better when falling asleep, or with anxiety medications)

___ Little to none (0) ___ Mild to Moderate (+2) ___ Very much so (+4)

2. Body changes that come with pain (skin color changes, sweating, blood pressure going up and down)

___ Little to none (0) ___ Mild to Moderate (+2) ___ Very much so (+4)

Target 2 Subtotal: ____/8

—

TARGET 3: Endogenous Opioid System Dysfunction

Score each item: 0 = No/Absent 1 = Mild 2 = Moderate. 3 = Marked

____ Depression or ongoing low mood that comes with pain

____ Anxiety or ongoing worry that comes with pain

____ Difficulty enjoying activities or things that used to bring pleasure

Duration of consistent daily opioid pain medication usen (Select only 1 best answer):

____ Not currently on opioids (0)

____ Less than 2 years (1)

____ 2 to 5 years (2)

____ 5 to 10 years (3)____ 10 to 20 years (4)

____ Greater than 20 years (5)

____ Have you been told by a doctor that you have PTSD, or been treated for PTSD?

No (0) Yes (3)

Target 3 Subtotal: ____ /17

—

TARGET 4: Neuroinflammatory / Glial Activation Features

Score each item: 0 = No 1 = Possible 2 = Probable 3 = Definite

____ Pain that started after an infection, surgery, or illness

____ Pain condition that your doctor has linked to nerve damage or nerve inflammation

(examples: pain from shingles, chemotherapy, complex regional pain, pain after

COVID)

____ Feeling tired, run down, or generally unwell along with pain

____ Sleep that does not leave you feeling rested

Target 4 Subtotal: ____/12

TARGET 5: Previous Medication Experience (Supplemental)

Rate your experiences:

5-1. Have you previously taken clonidine (Catapres) daily for more than 1 month (pill or patch)?

5A. If No, skip to question 5-2.

5B. If Yes, rate your benefit for pain:

___ Little to none (−1). ___ Mild to Moderate (+1). ___ Very effective (+3)

5-2. Have you previously taken tizanidine (Zanaflex) daily for more than 1 month?

5C. If No, screening is complete.

5D. If Yes, rate your benefit for pain:

___ Little to none (−1) Mild to Moderate (+2) Very effective (+5)

Target 5 Subtotal: ____/ (−2 to +8)

—

SCORING SUMMARY

Target 1 (Central Sensitization Features (NMDA/Neuroplasticity)): ____/21

Target 2 (α₂-Adrenergic / Imidazoline Receptor Responsiveness): ____/8

Target 3 (Endogenous Opioid System Dysfunction): ____/17

Target 4 (Neuroinflammatory / Glial Activation Features): ____/12

Core Subtotal (Targets 1–4): ____/58

Target 5 Previous Medication Experience (Supplemental): ____/ (−2 to +8)

ACST-P ADJUSTED TOTAL: _____ / (−2 to 66)

CANDIDACY SCORING STRATIFICATION

Strong: Adjusted Total ≥38 (≥65%)

• Pain features engage multiple agmatine targets

• Action: Initiate agmatine per protocol

Moderate: Adjusted Total 26–37 (44–64%)

• Consider if the strongest target aligns with the primary pain driver

• Action: Proceed if strongest target aligns with pain diagnosis; otherwise defer

Weak: Adjusted Total 15–25 (25–43%)

• Agmatine unlikely to be first-line supplement choice

• Action: Direct toward other approaches; reassess if pain features change

Poor: Adjusted Total 15 (25%)

• Poor fit with Agmatine’s mechanisms for analgesia

• Action: Consider potential use for suppression/reversal of opioid analgesic tolerance

Target-Dominant Profiles:

Target 1 dominant: Central sensitization symptom profile→ Agmatine’s NMDA antagonism is primary mechanism
Target 2 dominant: α₂/imidazoline-responsive symptom profile → strongest translational rationale (clonidine-displacing substance)
Target 3 dominant: Opioid system dysfunction → Agmatine’s β-endorphin release and tolerance prevention
Target 4 dominant: Neuroinflammatory symptom profile → I₂ receptor-mediated glial modulation

—

SAFETY SCREENING (complete before initiating Agmatine)

Relative contraindications / monitoring requirements:

Currently on clonidine or other α₂ agonist → Monitor for additive bradycardia (slow heart rate)
Currently on metformin, cimetidine, trimethoprim, or dolutegravir → Potential drug interactions)
Baseline heart rate: <60 bpm → bradycardia (slow heart rate) risk
Baseline systolic BP <100 mmHg → Hypotension risk (low blood pressure)
Renal impairment (eGFR <60) → Agmatine is renally cleared; dose adjustment may be needed
GI sensitivity or DAO (Diamine Oxidase) deficiency → Higher risk of GI side effects at doses >2.67 g/day
Pregnancy or lactation → No safety data

Suggested Starting Protocol:

Agmatine sulfate starting dose: 500 mg twice a day for the first week (after meals)
Therapeutic dose: 2,000 -3,000 mg/day (divided dose twice a day after meals)
Maximum studied dose: 3.56 g/day (used for 21 days in a research study)
Reassess pain, function and side effects at 4 weeks

TARGET-DOMINANT PROFILES

When the ACST-P Adjusted Total falls in the Moderate range (24–35), the strongest target guides the clinical decision:

Target 1 Dominant:

Central sensitization features → agmatine’s NMDA blocking action is the primary mechanism of benefit

Target 2 Dominant (with Target 5 support):

α₂/imidazoline-responsive features → strongest direct evidence for agmatine candidacy

Target 3 Dominant:

Endogenous opioid system dysfunction → Agmatine’s natural endorphin release and tolerance prevention mechanisms are primary

Target 4 Dominant:

Neuroinflammatory features → Agmatine’s nerve inflammation-calming action (I₂ receptor-mediated glial modulation) is the primary mechanism

HOW TARGET 5 MODIFIES CANDIDACY

Target 5 functions as a medication experience modifier that shifts the Adjusted Total relative to the core score:

1. No medication exposure (Target 5 = 0): Candidacy determined entirely by core assessment (Targets 1–4). This is the default for most patients.

2. Positive medication signal (Target 5 = +1 to +8): Provides medication experience-based evidence supporting Agmatine candidacy (when taking a medication previously with overlapping mechanisms of action shared by Agmatine helped pain). A patient at the top of the moderate range (core = 35) with strong tizanidine response (+5) reaches 40 → strong candidacy.

3. Negative medication signal (Target 5 = −1 to −2): Provides weak evidence against pain benefit from Agmatine (when taking a medication with overlapping mechanisms of action shared by Agmatine previously did NOT help pain). A patient at the bottom of the strong range (core = 36) with no benefit from both medications (−2) drops to 34 → moderate candidacy, requiring strongest-target alignment to proceed.

CLINICIAN SUPPLEMENT (Advisory — Non-Scoring)

The following supplement is for clinician use only. It does not add to the ACST-P score. It provides optional clinical context that may strengthen or temper the clinician’s interpretation of the ACST-P result, particularly for patients scoring in the Moderate range where the decision to proceed depends largely on clinical judgment.

The clinician may choose to engage any or all of the following assessments as clinically indicated:

A. Pain Catastrophizing Assessment

When clinical suspicion of catastrophizing exists, consider administering a validated short-form measure:

• PCS-6 (6-item Pain Catastrophizing Scale short form (r = 0.98 with full PCS)

• Brief PCS-4 (4-item version (r = 0.95 with full PCS)

• University of Washington Concerns About Pain (CAP) scale

A high catastrophizing score supports Target 3 (endogenous opioid dysfunction), as catastrophizing is associated with reduced endogenous opioid release during pain and greater mu-opioid receptor binding potential —the system Agmatine modulates via β-endorphin release.

B. Opioid-Induced Hyperalgesia (OIH) Risk Assessment

When clinical suspicion of OIH exists, the clinician may consider the following risk factors:

• High-risk opioid formulations: oxycodone, morphine, fentanyl

• Dose trajectory: escalating doses with diminishing analgesic return despite stable pain condition

• Clinical features: new-onset diffuse pain, expanding pain distribution, or increased pain sensitivity not explained by disease progression

OIH risk supports both Target 1 (NMDA-mediated central sensitization) and Target 3 (opioid system dysfunction), as OIH is driven by the same NMDA receptor upregulation that Agmatine antagonizes.

C. Standardized Screening Tool Integration

The clinician may incorporate results from validated instruments already in use:

•PHQ-9 score ≥10: Supports Target 3, Item 1 (depression concurrent with pain)

•Central Sensitization Inventory (CSI) score ≥40/100: Strongly supports Target 1

•NTSS-6 SA score ≥6: Supports Target 4 (neuropathic pain features

•Pain Catastrophizing Scale (PCS) score ≥30: Supports Target 3 via Supplement A above

These instruments provide quantitative precision to the patient’s self-reported responses and may help resolve borderline scores.

D. Biomarker Integration – ACST Pre-Treatment Optimization Module (PTOM)

Baseline laboratory testing is performed on all patients prior to initiating treatment with agmatine. Any abnormal lab testing will be addressed with corrective measures, including magnesium, RBC Mg levels and functional or measured levels of B vitamins. Elevated hs-CRP tests will be assessed for correctable conditions and addressed prior to initiating agmatine. Subsequent to these corrective measures, the following biomarker patterns may inform the clinician’s interpretation of ACST-P results:

• hs-CRP >3.0 mg/L (post-correction) without clear peripheral source:

→ Suggests persistent neuroinflammation despite metabolic optimization → supports Target 4. Agmatine’s I₂ receptor-mediated reduction of spinal TNF-α and glial activation markers (GFAP, Iba-1) is mechanistically relevant.

• Homocysteine remaining >15 µmol/L despite methylated B vitamin correction:

→ Suggests persistent NMDA agonist load → supports Target 1. Homocysteine is a direct NMDA receptor agonist; persistent elevation despite correction may indicate ongoing excitotoxic drive that agmatine’s NMDA antagonism could address. -> Consider MTHFR genotyping.

• RBC Magnesium remaining below reference range despite supplementation:

→ Suggests impaired endogenous NMDA channel blockade → supports Target 1. Magnesium is the physiological voltage-dependent NMDA channel blocker; persistent deficiency removes this protective mechanism.

• Vitamin D remaining 30 ng/mL despite supplementation:

→ Suggests persistent central sensitization contributor → supports Target 1.

• Elevated inflammatory markers (CRP, ESR, ferritin) without clear peripheral inflammatory source:

→ Supports Target 4.

• Elevated Uric Acid: May suggest oxidative stress burden relevant to neuroinflammatory pathways → contextually supports Target 4.

All metabolic markers normalized with PTOM:

→ Suggests metabolic correction may be sufficient; monitor clinical response before escalating to Agmatine.

E. Hypervigilance Assessment

When clinical suspicion of pain hypervigilance exists, consider administering the PVAQ-8 (8-item PainVigilance and Awareness Questionnaire). The PVAQ-8 measures two factors: active vigilance (deliberate scanning for pain) and passive awareness (involuntary intrusion of pain into consciousness).

Relevance to Agmatine candidacy:

Hypervigilance prevents engagement of the opioidergic ACC → PAG → RVM descending inhibitory pathway. Attentional analgesia — the brain’s ability to reduce pain by directing attention away from it is opioid-dependent. Blocking endogenous opioids with naltrexone impairs attentional analgesia and disrupts RVM-spinal and ACC-PAG connectivity.
Hypervigilant patients continuously direct attention toward pain, keeping this opioidergic circuit disengaged. High hypervigilance scores support Target 3 (endogenous opioid dysfunction) because the opioidergic descending inhibitory system cannot function when attention is locked onto pain.
High hypervigilance scores also support Target 1 (central sensitization) because the attentional amplification of pain signals drives NMDA receptor-mediated neuroplastic changes in prefrontal and limbic circuits.
Hypervigilance is part of a self-reinforcing loop: catastrophizing drives hypervigilance → hypervigilance prevents attentional analgesia → reduced endogenous opioid function → impaired salience filtering → amplified hypervigilance. Agmatine potentially intervenes at multiple points in this cycle via NMDA antagonism, β-endorphin release, and glial modulation.

When to deploy the PVAQ-8:

Consider the PVAQ-8 when a patient scores in the Moderate candidacy range (26–37) and the clinician suspects that hypervigilance is a significant contributor to the pain experience — particularly when Target 3 is the dominant target. A high PVAQ-8 score strengthens the case for proceeding with agmatine in borderline candidates.

Note: The ACST-P patient-facing section already captures the behavioral consequences of hypervigilance through Target 1 items 4–6 (heightened sensitivity, wind-up, thinking problems) and Target 3 items 1–2 (depression, anxiety). The PVAQ-8 provides quantitative precision to these self-reported observations.

F. PTSD Screening

When clinical suspicion of PTSD exists — or when the patient endorses Target 3, Item 5 (PTSD diagnosis) — the clinician may deploy the PC-PTSD-5 for further characterization. The PC-PTSD-5 is a 5-item, yes/no screener with excellent diagnostic accuracy (AUC = 0.93–0.94). The VA/DoD Clinical Practice Guideline recommends it for primary care PTSD screening. A cutoff score of ≥3 maximizes sensitivity (93–100%), and ≥4 maximizes efficiency (89% correct classification).

The PC-PTSD-5 items assess:

Nightmares or unwanted thoughts about the traumatic event
Avoidance of thoughts or reminders of the event
Hypervigilance or exaggerated startle
Emotional numbing or detachment
Guilt or blame related to the event

Relevance to agmatine candidacy:

PTSD involves NMDA-mediated maladaptive neuroplasticity (supports Target 1). Ketamine and lanicemine (NMDA antagonists) produce rapid PTSD symptom reductions, and agmatine has demonstrated efficacy in a PTSD animal model via both NMDA antagonism and imidazoline receptor engagement.
PTSD involves endogenous opioid system dysregulation (supports Target 3). PTSD patients show reduced resting plasma β-endorphin concentrations, altered µ-opioid receptor binding in limbic regions, and lower pain thresholds.
PTSD involves neuroinflammation with elevated proinflammatory cytokines (supports Target 4).
PTSD involves central noradrenergic hyperactivity (supports Target 2). Clonidine has been studied specifically for PTSD hyperarousal symptoms, creating a direct mechanistic bridge to Target 5.
The “numbness/detachment” symptom cluster (PC-PTSD-5 Item 4) is the most strongly associated with negative pain outcomes in chronic pain populations.

When to deploy the PC-PTSD-5 :

When a patient endorses Target 3, Item 5 but the clinician wants to characterize PTSD severity or symptom profile•When a patient does not endorse Target 3, Item 5 but the clinician suspects undiagnosed trauma-related pathology (approximately 27% of chronic pain patients meet PTSD screening criteria)
When a patient scores in the Moderate candidacy range and the clinician suspects that trauma-related pathology may be an unrecognized contributor to the pain phenotype
A positive PC-PTSD-5 screen in a patient who did not endorse Target 3, Item 5 suggests undiagnosed PTSD and strengthens the case for agmatine candidacy across Targets 1, 3, and 4 simultaneously.

This finding may also warrant referral for formal PTSD evaluation and treatment.

G. Prophylaxis of Opioid Analgesic Tolerance (OAT)

Reflecting on Agmatine’s potential for suppressing or even reversing opioid analgesic tolerance (OAT), consideration can be given to the use of Agmatine prophylactically in patients on chronic opioid management. To help reduce the evolution of OAT, one may preferentially consider Agmatine use concurrent with opioids having greater propensity for developing OAT more rapidly than others (morphine, hydromorphone, oxycodone).

Rationale: Independent of the ACST-P candidacy score, agmatine supplementation may be considered prophylactically in patients on chronic opioid therapy to suppress or slow the development of opioid analgesic tolerance (OAT).

Preclinical evidence demonstrates that agmatine prevents, moderates, or reverses opioid-induced tolerance through multiple mechanisms:

• NMDA receptor antagonism (preferentially GluN2B-containing receptors in the spinal cord dorsal horn), which blocks the glutamate-dependent neuroplasticity underlying tolerance development

• Anti-neuroinflammatory effects (suppression of TNF-α, IL-6, IL-1β, and microglial activation), which counteract the neuroinflammatory component of tolerance

• Enhancement of opioid analgesia (5- to 9-fold shift in morphine ED₅₀ at spinal level), which may allow lower opioid doses to achieve equivalent analgesia

• Blood-brain barrier protection, which reduces peripheral cytokine infiltration into the CNS during chronic opioid exposure

Opioid-Specific Risk Stratification for OAT

Not all opioids develop analgesic tolerance at the same rate or through the same mechanisms. The following stratification may guide prioritization of agmatine prophylaxis:

Higher Priority:

Opioids with greater OAT propensity and stronger mechanistic rationale for agmatine co-administration:

• Morphine: Develops tolerance through both impaired MOR resensitization and accumulation of morphine-3-glucuronide (M3G), a metabolite that promotes hyperalgesia via TLR4/MD-2 neuroinflammatory signaling and NMDA receptor activation. Agmatine directly counteracts both mechanisms. Strongest preclinical evidence base for agmatine anti-tolerance effects.

• Hydromorphone: Shares the M3G metabolite liability with morphine. During dose escalation or renal impairment, M3G accumulation can counteract analgesic potency. Same mechanistic rationale as morphine for agmatine co-administration.

• Oxycodone: Lower intrinsic MOR efficacy than morphine, which paradoxically may produce more tolerance at equi-effective doses through distinct cellular mechanisms. Does not produce M3G but develops tolerance through altered kinase regulation of GPCRs. Agmatine has demonstrated potentiation of oxycodone analgesia through α₂-adrenoceptor and imidazoline receptor mechanisms.

Moderate Priority:

Opioids with modified tolerance profiles:

• Fentanyl: High intrinsic efficacy with efficient MOR internalization/recycling may partially protect against some tolerance mechanisms. However, high potency and rapid binding kinetics may accelerate tolerance through alternative pathways. Agmatine prophylaxis is reasonable during chronic transdermal fentanyl therapy.

Lower Priority

Opioids with intrinsic anti-tolerance properties:

• Methadone: Possesses intrinsic NMDA receptor antagonist activity, which partially overlaps with agmatine’s primary anti-tolerance mechanism. Agmatine may still provide additive benefit through non-NMDA mechanisms (neuroinflammatory suppression, β-endorphin release), but the mechanistic rationale is less compelling than for morphine/hydromorphone/oxycodone.

• Buprenorphine: As a partial MOR agonist with κ-opioid receptor antagonism, buprenorphine has a distinct tolerance profile and may reverse OIH. Agmatine prophylaxis is lowest priority in this group.

Clinical Application

When considering Agmatine for OAT prophylaxis independent of the ACST-P candidacy score:

1. Patients on chronic morphine, hydromorphone, or oxycodone who demonstrate escalating dose requirements despite stable pain conditions are the highest-priority candidates.

2. Patients initiating long-term opioid therapy with morphine, hydromorphone, or oxycodone may benefit from concurrent agmatine initiation to delay tolerance onset.

3. The same safety screening (hemodynamic parameters, renal function, drug interactions) and dosing protocol apply as for ACST-P-indicated agmatine use.

4. Monitor for opioid-sparing effects — agmatine’s enhancement of opioid analgesia may allow dose reduction. Dose adjustments should be made cautiously with appropriate monitoring.

5. If concurrent clonidine or tizanidine therapy is present, follow the hemodynamic monitoring protocols outlined in the ART-8 framework.

Important Caveat: The evidence for agmatine’s anti-tolerance effects is derived entirely from preclinical (animal) studies. No human clinical trials have specifically evaluated agmatine for OAT prophylaxis. Clinical application represents translational extrapolation from robust preclinical data and should be monitored accordingly.

Key Considerations for OAT

The opioid-specific stratification is more nuanced than a simple list of “high-risk” opioids. The evidence reveals that tolerance develops through at least three distinct mechanisms that vary by opioid:

1. NMDA receptor-mediated spinal neuroplasticity — the primary mechanism for morphine tolerance, directly blocked by agmatine’s GluN2B antagonism[18][19][20][21]

2. M3G metabolite-driven neuroinflammation — specific to morphine and hydromorphone, counteracted by agmatine’s TLR4/NF-κB modulation and microglial suppression[8][9][10][11][12]

3. Altered kinase regulation of GPCRs — the primary mechanism for oxycodone tolerance, which operates through a different cellular pathway than morphine tolerance[15]

Agmatine addresses mechanisms 1 and 2 most directly, which is why morphine and hydromorphone represent the highest-priority candidates. Oxycodone tolerance operates partly through mechanism 3, but agmatine’s demonstrated potentiation of oxycodone analgesia through α₂-adrenoceptor and imidazoline receptor mechanisms provides an alternative rationale for co-administration.[5]

The important caveat about the exclusively preclinical evidence base is essential. While the preclinical data are remarkably consistent across multiple laboratories, species, and experimental paradigms — including the elegant immunoneutralization and gene therapy studies from the Fairbanks laboratory — no human trial has specifically tested agmatine for OAT prophylaxis.[1][2][3] The human safety trial (2.67 g/day for 5 years) confirmed long-term safety but did not assess opioid tolerance outcomes.[22]

I. Additional Clinical Observations

The clinician may note any other clinical observations that inform their interpretation of the ACST-P result, including but not limited to:

• Response to other NMDA-modulating agents (e.g., ketamine infusions, memantine, dextromethorphan)

• Quantitative sensory testing results if available

• Specific pain diagnoses with known neuroinflammatory components (CRPS, chemotherapy-induced neuropathy, post-herpetic neuralgia, post-COVID pain syndromes)

• Any other clinical features the clinician considers relevant to Agmatine candidacy

Using the Clinician Supplement:

This supplement is designed to be flexible. The clinician reviews the ACST-P score, considers any applicable supplement items, and makes a final clinical determination. No additional scoring is required. The supplement is most valuable for patients in the Moderate candidacy range (24–35), where clinical judgment determines whether to proceed. For patients in the Strong or Poor ranges, the ACST-P score alone is generally sufficient to guide thedecision.

Practitioners not using the PTOM lab panel or who do not routinely assess catastrophizing may omit those sections without affecting the validity of the ACST-P core assessment.

References

1.Immunoneutralization of Agmatine Sensitizes Mice to Micro-Opioid Receptor Tolerance. Wade CL, Eskridge LL, Nguyen HO, et al. The Journal of Pharmacology and Experimental Therapeutics. 2009;331(2):539-46. doi:10.1124/jpet.109.155424.

2.Supraspinally Administered Agmatine Prevents the Development of Supraspinal Morphine Analgesic Tolerance. Kitto KF, Fairbanks CA. European Journal of Pharmacology. 2006;536(1-2):133-7. doi:10.1016/j.ejphar.2006.01.053.

3.Adeno-Associated Virus-Mediated Gene Transfer of Arginine Decarboxylase to the Central Nervous System Prevents Opioid Analgesic Tolerance. Churchill CC, Peterson CD, Kitto KF, et al. Frontiers in Pain Research (Lausanne, Switzerland). 2023;4:1269017. doi:10.3389/fpain.2023.1269017.

4.Modulation of Opioid Analgesia by Agmatine. Kolesnikov Y, Jain S, Pasternak GW. European Journal of Pharmacology. 1996;296(1):17-22. doi:10.1016/0014-2999(95)00669-9.

5.Determination of Α(2)-Adrenoceptor and Imidazoline Receptor Involvement in Augmentation of Morphine and Oxycodone Analgesia by Agmatine and BMS182874. Bhalla S, Rapolaviciute V, Gulati A. European Journal of Pharmacology. 2011;651(1-3):109-21. doi:10.1016/j.ejphar.2010.10.090.

6.Agmatine Ameliorates Morphine-Induced Behavioral Sensitization Through Blood-Brain Barrier Protection and Anti-Neuroinflammatory Effects in the Nucleus Accumbens. Ma H, Tian W, Xiao J, et al. Psychopharmacology. 2025;:10.1007/s00213-025-06944-2. doi:10.1007/s00213-025-06944-2.

7.Mechanisms of Rapid Opioid Receptor Desensitization, Resensitization and Tolerance in Brain Neurons. Dang VC, Christie MJ. British Journal of Pharmacology. 2012;165(6):1704-1716. doi:10.1111/j.1476-5381.2011.01482.x.

8.Opioid Tolerance in Critical Illness. Martyn JAJ, Mao J, Bittner EA. The New England Journal of Medicine. 2019;380(4):365-378. doi:10.1056/NEJMra1800222.

9.Morphine-3-Glucuronide Causes Antinociceptive Cross-Tolerance to Morphine and Increases Spinal Substance P Expression. Blomqvist KJ, Viisanen H, Ahlström FHG, et al. European Journal of Pharmacology. 2020;875:173021. doi:10.1016/j.ejphar.2020.173021.

10.Morphine-Induced Hyperalgesia Involves Mu Opioid Receptors and the Metabolite Morphine-3-Glucuronide. Roeckel LA, Utard V, Reiss D, et al. Scientific Reports. 2017;7(1):10406. doi:10.1038/s41598-017-11120-4.

11.Morphine-3-Glucuronide, Physiology and Behavior. Gabel F, Hovhannisyan V, Berkati AK, Goumon Y. Frontiers in Molecular Neuroscience. 2022;15:882443. doi:10.3389/fnmol.2022.882443.

12.Neuroexcitatory Effects of Morphine-3-Glucuronide Are Dependent on Toll-Like Receptor 4 Signaling. Due MR, Piekarz AD, Wilson N, et al. Journal of Neuroinflammation. 2012;9:200. doi:10.1186/1742-2094-9-200.

13.Opioid Agonist Efficacy Predicts the Magnitude of Tolerance and the Regulation of Mu-Opioid Receptors and Dynamin-2. Pawar M, Kumar P, Sunkaraneni S, et al. European Journal of Pharmacology. 2007;563(1-3):92-101. doi:10.1016/j.ejphar.2007.01.059.

14.Neurophysiological Response Properties of Medullary Pain-Control Neurons Following Chronic Treatment With Morphine or Oxycodone: Modulation by Acute Ketamine. Viisanen H, Lilius TO, Sagalajev B, et al. Journal of Neurophysiology. 2020;124(3):790-801. doi:10.1152/jn.00343.2020.

15.Agonist-Specific Regulation of G Protein-Coupled Receptors After Chronic Opioid Treatment. Adhikary S, Koita O, Lebowitz JJ, Birdsong WT, Williams JT. Molecular Pharmacology. 2022;101(5):300-308. doi:10.1124/molpharm.121.000453.

16.Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury. Kosten TR, Graham DP, Nielsen DA. JAMA Psychiatry. 2018;75(6):642-648. doi:10.1001/jamapsychiatry.2018.0101.17.Morphine and Fentanyl Differently Affect MOP and NOP Gene Expression in Human Neuroblastoma SH-SY5Y Cells. Caputi FF, Lattanzio F, Carretta D, et al. Journal of Molecular Neuroscience : MN. 2013;51(2):532-8. doi:10.1007/s12031-013-0019-3.

18.Agmatine Preferentially Antagonizes GluN2B-containing N-Methyl-D-Aspartate Receptors in Spinal Cord. Waataja JJ, Peterson CD, Verma H, et al. Journal of Neurophysiology. 2019;121(2):662-671. doi:10.1152/jn.00172.2018.

19.Targeting Excitatory Glutamate Receptors for Morphine Tolerance: A Narrative Review. Huang M, Luo L, Wang W, et al. CNS Neuroscience & Therapeutics. 2025;31(6):e70468. doi:10.1111/cns.70468.

20.Chronic Opioid Potentiates Presynaptic but Impairs Postsynaptic N-Methyl-D-Aspartic Acid Receptor Activity in Spinal Cords: Implications for Opioid Hyperalgesia and Tolerance. Zhao YL, Chen SR, Chen H, Pan HL. The Journal of Biological Chemistry. 2012;287(30):25073-85. doi:10.1074/jbc.M112.378737.

21.Inhibition of Opiate Tolerance by Non-Competitive N-Methyl-D-Aspartate Receptor Antagonists. Trujillo KA, Akil H. Brain Research. 1994;633(1-2):178-88. doi:10.1016/0006-8993(94)91538-5.

22.Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence. Regunathan S. The AAPS Journal. 2006;8(3):E479-84. doi:10.1208/aapsj080356.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.